Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Efficacy of intravenous levosimendan in patients with heart failure complicated by acute myocardial infarction.

Jia Z, Guo M, Zhang YQ, Liang HQ, Zhang LY, Song Y.

Cardiology. 2014;128(2):195-201. doi: 10.1159/000357864. Epub 2014 Apr 16.

PMID:
24751462
2.

Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).

Moiseyev VS, Põder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS, Lie KI; RUSSLAN Study Investigators..

Eur Heart J. 2002 Sep;23(18):1422-32.

PMID:
12208222
3.

Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.

Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, Hutchins S, Leier CV, LeJemtel TH, Loh E, Nicklas J, Ogilby D, Singh BN, Smith W.

Circulation. 2000 Oct 31;102(18):2222-7.

4.
5.

Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study.

Husebye T, Eritsland J, Müller C, Sandvik L, Arnesen H, Seljeflot I, Mangschau A, Bjørnerheim R, Andersen GØ.

Eur J Heart Fail. 2013 May;15(5):565-72. doi: 10.1093/eurjhf/hfs215. Epub 2013 Jan 2.

6.

ST-segment elevation during levosimendan infusion.

Barillà F, Giordano F, Jacomelli I, Pellicano M, Dominici T.

J Cardiovasc Med (Hagerstown). 2012 Jul;13(7):454-6. doi: 10.2459/JCM.0b013e3283559af6.

PMID:
22673026
7.

Levosimendan and nesiritide as a combination therapy in patients with acute heart failure.

Jia Z, Guo M, Zhang LY, Zhang YQ, Liang HQ, Song Y.

Am J Med Sci. 2015 May;349(5):398-405. doi: 10.1097/MAJ.0000000000000461.

PMID:
25853935
8.

Utility of the neutrophil to lymphocyte ratio for predicting in-hospital mortality after levosimendan infusion in patients with acute decompensated heart failure.

Tasal A, Erturk M, Uyarel H, Karakurt H, Bacaksiz A, Vatankulu MA, Turfan M, Sonmez O, Erdogan E, Ergelen M.

J Cardiol. 2014 Jun;63(6):418-23. doi: 10.1016/j.jjcc.2013.10.009. Epub 2013 Nov 20.

9.

Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.

Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, Nyquist O, Remme WJ.

J Am Coll Cardiol. 2000 Nov 15;36(6):1903-12.

10.

Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.

Parle NM, Thomas MD, Dembo L, Best M, Driscoll GO.

Heart Lung Circ. 2008 Jun;17(3):206-10. doi: 10.1016/j.hlc.2007.10.014. Epub 2008 Jan 31.

PMID:
18242130
11.

[Levosimendan in heart failure].

Scelsi L, Campana C, Ghio S, Monti L, Opasich C, De Feo S, Cobelli F, Orlandi M, Di Pasquale G, Tavazzi L.

Recenti Prog Med. 2004 Jul-Aug;95(7-8):376-83. Review. Italian.

PMID:
15303549
12.

Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort. Results of the BELIEF study.

Bocchi EA, Vilas-Boas F, Moreira Mda C, Barretto AC, Lage S, Albuquerque D, Baima J, Rassi S, Ribeiro JP; Investigators of BELIEF Study.; Heart Failure Working Group of Brazilian Society of Cardiology..

Arq Bras Cardiol. 2008 Mar;90(3):182-90. English, Portuguese.

13.

Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.

Follath F.

Ital Heart J. 2003 May;4 Suppl 2:34S-38S.

PMID:
14635368
14.

Management of acute cardiac failure by intracoronary administration of levosimendan.

Caimmi PP, Kapetanakis EI, Beggino C, Molinari C, Giustini G, Crosio E, Reposo G, Micalizzi E, Vacca G, Grossini E.

J Cardiovasc Pharmacol. 2011 Sep;58(3):246-53. doi: 10.1097/FJC.0b013e318220e491.

PMID:
21654504
15.

Levosimendan increases bleeding risk after heart valve surgery: a retrospective analysis of a randomized trial.

Lahtinen P, Pitkänen O, Musialowicz T.

J Cardiothorac Vasc Anesth. 2014 Oct;28(5):1238-42. doi: 10.1053/j.jvca.2014.04.022.

PMID:
25281042
16.

Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial.

Lahtinen P, Pitkänen O, Pölönen P, Turpeinen A, Kiviniemi V, Uusaro A.

Crit Care Med. 2011 Oct;39(10):2263-70. doi: 10.1097/CCM.0b013e3182227b97.

PMID:
21666445
17.

Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure.

Parissis JT, Adamopoulos S, Farmakis D, Filippatos G, Paraskevaidis I, Panou F, Iliodromitis E, Kremastinos DT.

Heart. 2006 Dec;92(12):1768-72. Erratum in: Heart. 2009 Jan;95(1):84.

18.

Rationale and design of a randomized, double-blind, placebo controlled multicenter trial to study efficacy, security, and long term effects of intermittent repeated levosimendan administration in patients with advanced heart failure: LAICA study.

García-González MJ, de Mora-Martín M, López-Fernández S, López-Díaz J, Martínez-Sellés M, Romero-García J, Cordero M, Lara-Padrón A, Marrero-Rodríguez F, del Mar García-Saiz M, Aldea-Perona A; LAICA study investigators..

Cardiovasc Drugs Ther. 2013 Dec;27(6):573-9. doi: 10.1007/s10557-013-6476-7.

19.
20.

[Therapy of acute decompensated heart failure with levosimendan].

Müller K, Peters A, Zeus T, Hennersdorf M, Strauer BE.

Med Klin (Munich). 2006 Mar 22;101 Suppl 1:119-22. German.

PMID:
16802535

Supplemental Content

Support Center